Consequently, all patients requiring specific, potentially life-saving drugs should be provided with in-date drug formulations for all markets across Europe. Failure to do so results in stock-outs. In these situations, patient lives are at risk. So risks patient lives, but stock-outs have occurred even when a manufacturer has based its production on local demand. These stock-outs have occurred as a result of parallel trade. In these situations following launch. These situations form a useful series of case studies to further investigate country specific requirements for identified short cut routes to market access and reimbursement for orphan drug hospital only medicines (OD-HOM) in EU countries. The results of the ongoing OD-HOM research will be displayed as a summary.